Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions

Keyphrases

• Metastatic Renal Cell Carcinoma (mRCC) 100%
• Immune Checkpoint Inhibitors 80%
• Systemic Therapy 60%
• Recent Innovation 40%
• Immune Response 20%
• Tumor Cells 20%
• Tolerability 20%
• Patient Outcomes 20%
• Response Rate 20%
• Antiangiogenic Agents 20%
• Objective Response Rate 20%
• Cell Destruction 20%
• Complete Response Rate 20%
• Immune-related Adverse Events 20%
• Cost Implications 20%
• Recent Trends 20%
• First-line Therapy 20%
• Overall Survival Progression-free Survival 20%

Medicine and Dentistry

• Immunotherapy 100%
• Kidney Metastasis 100%
• Immune Checkpoint Inhibitor 80%
• Systemic Therapy 60%
• Cytokine 40%
• Health Care Cost 20%
• Neck 20%
• Progression Free Survival 20%
• Overall Survival 20%
• Angiogenesis Inhibitor 20%
• Immune-Related Adverse Events 20%
• Tumor Cell Destruction 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Immunotherapy 100%
• Kidney Metastasis 100%
• Immune Checkpoint Inhibitor 80%
• Cytokine 40%
• Adverse Event 20%
• Neoplasm 20%
• Overall Survival 20%
• Tolerability 20%
• Progression Free Survival 20%
• Angiogenesis Inhibitor 20%